View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

Sarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing Tuesday a deal with Arrowhead Pharmaceuticals that will give it four clinical ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three ...

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system ...

(RTTNews) - Arrowhead Pharmaceuticals (ARWR), a clinical-stage biotech company, announced, on Tuesday, that it has entered into a global licensing and collaboration agreement with Sarepta ...

After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets for rare genetic diseases, Leerink analyst Joseph ...

Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD) in the next few months, with a view to ...

Cantor Fitzgerald analyst Kristen Kluska upgraded Sarepta (SRPT) to Overweight from Neutral with a price target of $167, up from $152. The company reported Q3 earnings, the first full quarter ...

In June, the FDA expanded its approval of Sarepta Therapeutics’ Elevidys gene therapy for Duchenne muscular dystrophy to all patients ages four and older. The one-time treatment (which costs $3. ...

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT), Tuesday announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (ARWR) for multiple clinical, pre-clinical ...